MannKind Donates Afrezza® to Support People with Diabetes Impacted by Hurricane Maria in Puerto Rico
WESTLAKE VILLAGE, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced the company's support for Hurricane Maria victims in Puerto Rico with a donation of Afrezza® (insulin human) inhalation powder. The donation will be delivered via American Family Airlift (AFA), a relief organization established by Hector Hoyos and Dr. Cesar Sierra —two Puerto Rican natives passionate about helping those in need. Dedicated to gathering medical supplies and helping coordinate the airlift of these medical supplies to Puerto Rico, the AFA has partnered with a number of hospitals and organizations to assist with their relief efforts.
"Puerto Rico has one of the highest percentages of adults with diabetes in the United States,"1 said Michael Castagna, Chief Executive Officer of MannKind Corporation. "It is our duty to help. Hundreds of thousands of residents have been significantly impacted by Hurricane Maria, many of them with diabetes. With so many people unable to gain access to their medical supplies, having access to an inhaled insulin such as Afrezza, can provide support to adults living with diabetes in the affected communities."
Available by prescription only, Afrezza is a rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. This is the second donation, of Afrezza, MannKind has made over the past two months to help with relief efforts for recent hurricanes. For more information, including important safety information, on Afrezza, visit www.afrezza.com.
"Recovering from a disaster, such as the one left behind by Hurricane Maria, is challenging," said Castagna. "We hope that our support of people with diabetes will provide some relief on their long road to recovery, and we will continue to assess opportunities to assist people who, by circumstance, have no access to their supplies."
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
SVP, Investor Relations
Exchange: (US Dollar)
Data as of
08/17/18 4:32 PM EDT.
Copyright Nasdaq. Minimum 15 minutes delayed.
Learn more about MannKind's offices in the United States